Endogenous nociceptin/orphanin FQ (N/OFQ) contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: a combined microdialysis and behavioral study in naïve and nociceptin/orphanin FQ receptor knockout mice

Neuroscience

Volumn 166, Issue 1, 2010, Pages 40-48

  Mabrouk, O S ^a   Marti, M ^a   Morari, M ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

GABA; glutamate; haloperidol; microdialysis; nociceptin orphanin FQ; NOP receptor knockouts

Indexed keywords

1 (1 CYCLOOCTYLMETHYL 3 HYDROXYMETHYL 4 PIPERIDYL) 3 ETHYL 1,3 DIHYDRO 2H BENZIMIDAZOL 2 ONE; GLUTAMIC ACID; HALOPERIDOL; NOCICEPTIN; NOCICEPTIN RECEPTOR ANTAGONIST; UFP 101; UNCLASSIFIED DRUG;

4 AMINOBUTYRIC ACID RELEASE; AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; DRUG DOSE COMPARISON; DRUG EFFICACY; MICRODIALYSIS; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; ROTAROD TEST; SINGLE DRUG DOSE; SUBSTANTIA NIGRA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZIMIDAZOLES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; EXTRACELLULAR FLUID; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HALOPERIDOL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICRODIALYSIS; NEUROPHARMACOLOGY; OPIOID PEPTIDES; PARKINSONIAN DISORDERS; PIPERIDINES; RECEPTORS, OPIOID; SUBSTANTIA NIGRA; SYNAPTIC TRANSMISSION;

EID: 74449089442     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2009.12.006     Document Type: Article

References (27)

1. Brown J.M., Gouty S., Iyer V., Rosenberger J., and Cox B.M. Differential protection against MPTP or methamphetamine toxicity in dopamine neurons by deletion of ppN/OFQ expression. J Neurochem 98 (2006) 495-505
2. 2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. Br J Pharmacol 136 (2002) 303-311
3. Deniau J.M., and Chevalier G. Disinhibition as a basic process in the expression of striatal functions. II. The striato-nigral influence on thalamocortical cells of the ventromedial thalamic nucleus. Brain Res 334 (1985) 227-233
4. Di Benedetto M., Cavina C., D'Addario C., Leoni G., Candeletti S., Cox B.M., and Romualdi P. Alterations of N/OFQ and NOP receptor gene expression in the substantia nigra and caudate putamen of MPP(+) and 6-OHDA lesioned rats. Neuropharmacology 56 (2009) 761-767
5. Koizumi M., Midorikawa N., Takeshima H., and Murphy N.P. Exogenous, but not endogenous nociceptin modulates mesolimbic dopamine release in mice. J Neurochem 89 (2004) 257-263
6. Kuschinsky K., and Hornykiewicz O. Morphine catalepsy in the rat: relation to striatal dopamine metabolism. Eur J Pharmacol 19 (1972) 119-122
7. Mabrouk O.S., Volta M., Marti M., and Morari M. Stimulation of delta opioid receptors located in substantia nigra reticulata but not globus pallidus or striatum restores motor activity in 6-hydroxydopamine lesioned rats. New insights into the role of delta receptors in parkinsonism. J Neurochem 107 (2008) 1647-1659
8. Marti M., Guerrini R., Beani L., Bianchi C., and Morari M. Nociceptin/orphanin FQ receptors modulate glutamate extracellular levels in the substantia nigra pars reticulata. A microdialysis study in the awake freely moving rat. Neuroscience 112 (2002) 153-160
9. Marti M., Mela F., Veronesi C., et al. Blockade of nociceptin/orphanin FQ receptor signalling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behaviour. J Neurosci 24 (2004) 6659-6666
10. Marti M., Mela F., Guerrini R., Calò G., Bianchi C., and Morari M. Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release. J Neurochem 91 (2004) 1501-1504
11. Marti M., Mela F., Fantin M., et al. Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease. J Neurosci 95 (2005) 9591-9601
12. Marti M., Trapella C., Viaro R., and Morari M. The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway. J Neurosci 27 (2007) 1297-1307
13. Marti M., Trapella C., and Morari M. The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway. Positive interaction with L-DOPA. J Neurochem 107 (2008) 1683-1696
14. Marti M., Viaro R., Guerrini R., Franchi G., and Morari M. Nociceptin/Orphanin FQ modulates motor behavior and primary motor cortex output through receptors located in substantia nigra reticulata. Neuropsychopharmacology 34 (2009) 341-355
15. Meunier J.C., Mollerau C., Toll L., et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 377 (1995) 532-535
16. Mierau J., and Schingnitz G. Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. Eur J Pharmacol 215 (1992) 161-170
17. Mogil J.S., and Pasternak G.W. The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. Pharmacol Rev 53 (2001) 381-415
18. Mollereau C., Parmentier M., Mailleux P., Butour J.L., Moisand C., Chalon P., Caput D., Vassart G., and Meunier J.C. ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett 341 (1994) 33-38
19. Murphy N.P., Lam H.A., Chen Z., Pintar J.E., and Maidment N.T. Heroin-induced locomotion and mesolimbic dopamine release is unchanged in mice lacking the ORL 1 receptor gene. Brain Res 953 (2002) 276-280
20. Nishi M., Houtani T., Noda Y., et al. Unrestrained nociceptive response and dysregulation of hearing ability in mice lacking the nociceptin/orphaninFQ receptor. EMBO J 16 (1997) 1858-1864
21. Paxinos G., and Franklin K.B.J. The mouse brain in stereotaxic coordinates (2001), Academic Press, San Diego
22. Reinscheid R.K., Nothacker H.P., Bourson A., et al. Orphanin FQ: a neuropeptide that activates an opioid-like G protein-coupled receptor. Science 270 (1995) 792-794
23. Rozas G., Guerra M.J., and Labandeira-Garcia J.L. An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Res Brain Res Protoc 2 (1997) 75-84
24. Sanberg P.R., Bunsey M.D., Giordano M., and Norman A.B. The catalepsy test: its ups and downs. Behav Neurosci 102 (1988) 748-759
25. Schallert T., De Ryck M., Whishaw I.Q., Ramirez V.D., and Teitelbaum P. Excessive bracing reactions and their control by atropine and L-DOPA in an animal analog of Parkinsonism. Exp Neurol 64 (1979) 33-43
26. Siuciak J.A., and Fujiwara R.A. The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors. Psychopharmacology 175 (2004) 163-169
27. Viaro R., Sanchez-Pernaute R., Marti M., Trapella C., Isacson O., and Morari M. Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism. Neurobiol Dis 30 (2008) 430-438